A Phase II, Open Label, Randomised, Single Centre Study To Evaluate The Importance Of Naturally Induced Immune Regulation On The Mucosal Immune Response To Meningococcal Serogroup B Outer Membrane Vesicle (Omv) Vaccine When Administered Intramuscularly To Adults and Adolescents
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2016
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- 03 Feb 2012 Planned end date changed from 1 Feb 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 27 Jan 2010 Actual initiation date (Sep 2009) added as reported by ClinicalTrials.gov.
- 27 Jan 2010 Planned end date changed from 1 Feb 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.